Picture [LSA] – The Business Web Portal 650x89px
Organisation › Details

Polyphor Ltd. (SIX: POLN)

Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the Swiss Stock Exchange (SIX: POLN). *


Period Start 2011-07-27 existent
Products Industry antibiotic
  Industry 2 murepavadin (POL7080)
Persons Person Di Nepi, Giacomo (Polyphor 201611– CEO before InterMune + Takeda + McKinsey)
  Person 2 Scott, Kalina (Polyphor 201706– CFO before Bank am Bellevue + UBS + KPMG)
Region Region Allschwil BL
  Country Switzerland
  Street 125 Hegenheimermattweg
  City 4123 Allschwil BL
  Tel +41-61-567-1600
    Address record changed: 2018-07-24
Basic data Employees C: 51 to 100 (2013-11-04)
  Currency CHF
  Annual sales 6,545,595 (revenue, total, consolidated (2018) 2018-12-31)
  Profit -50,920,282 (2018-12-31)
  Cash 113,809,266 (2018-12-31)
    * Document for �About Section�: Polyphor Ltd.. (7/17/18). "Press Release: Polyphor Announces Listing of New Shares Related to the Convertible Loan Facility Agreement with the Wellcome Trust (Ad-hoc Announcement)".
Record changed: 2019-06-27


Picture [LSA] – The Business Web Portal 650x89px

More documents for Polyphor Ltd. (SIX: POLN)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top